Furthermore, the expression levels SV2B suggested that it can act as a prognostic marker, enhancing its clinical relevance in combating yet incurable highly malignant brain tumours, such as glioblastoma and medulloblastoma. This evidence concerns the gene SV2B and brain neoplasm.